Search company, investor...
Azur Pharma company logo

Azur Pharma

azurpharma.com

Founded Year

2005

About Azur Pharma

Azur Pharma is a pharmaceutical company focused on the CNS, women's health and urology markets of the US.

Headquarters Location

45 Fitzwilliam Square

2,

Ireland

Missing: Azur Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Azur Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Azur Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Azur Pharma is included in 1 Expert Collection, including Women's Health & Wellness.

W

Women's Health & Wellness

1,482 items

Startups focused on providing products and services catering to women's health and wellbeing.

Azur Pharma Patents

Azur Pharma has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/5/2011

9/18/2012

Analgesics, Calcium channel blockers, Piperidines, Synthetic opioids, Phenols

Grant

Application Date

7/5/2011

Grant Date

9/18/2012

Title

Related Topics

Analgesics, Calcium channel blockers, Piperidines, Synthetic opioids, Phenols

Status

Grant

Latest Azur Pharma News

Emergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of Directors

Feb 12, 2019

| Source: Emergent BioSolutions GAITHERSBURG, Md., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS ) today announced the appointment of Seamus Mulligan to the company’s Board of Directors effective March 19, 2019. Mr. Mulligan was a co-founder and principal investor of Adapt Pharma Ltd. and served as its chairman and CEO from 2014 until 2018, when Adapt was acquired by Emergent. “The appointment of Seamus to Emergent’s Board comes at a pivotal time in the company’s history, when successive acquisitions have resulted in rapid growth and expansion,” said Fuad El-Hibri, executive chairman of the board of Emergent BioSolutions. “As Emergent continues to focus on its mission – to protect and enhance life – by providing preparedness solutions to a wide range of public health threats, we welcome Seamus’ broad executive management experience and his entrepreneurial spirit that we believe will benefit the company for the long-term.” “It is an honor to be appointed to serve on the board of Emergent BioSolutions, whose growth in the last twenty years has been steady and impressive – addressing a niche market while honing its skills and evolving its core competencies to better serve and grow with its customers,” said Mr. Mulligan. “I look forward to contributing to Emergent's continued success and leveraging my business experience to assist the management team and the company in achieving their goals.” Mr. Mulligan is also the founder of Azur Pharma, where he served as chairman and CEO and as a member of its board of directors from 2005 until Azur merged with Jazz Pharmaceuticals in 2012. He served as chief business officer, international business development for Jazz until 2013. Prior to his tenure at Azur, Mr. Mulligan spent 20 years of his professional career with Elan Corporation, where he was responsible for a broad range of R&D and commercial operations and was closely involved in Elan’s growth and evolution from a drug delivery company into a research-focused pharmaceutical organization. At Elan, he served in progressive executive positions, including EVP of business and corporate development, EVP, corporate development, and president, Elan Pharmaceutical Technologies, a subsidiary of Elan. Mr. Mulligan’s senior operational positions include VP for product development, VP U.S. operations, and EVP pharmaceutical operations. Mr. Mulligan currently serves as a director of Jazz Pharmaceuticals Public Limited Company. Previous board memberships include serving as executive chairman of Circ Pharma Limited, chairman of the board and director of Azur Pharma Limited, and director of the U.S. National Pharmaceutical Council. He has a B.Sc (Pharm) and M.Sc from Trinity College, Dublin, Ireland. About Emergent BioSolutions Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats. We aspire to be a Fortune 500 company recognized for protecting and enhancing life, driving innovation, and living our values. Additional information about the company may be found at  www.emergentbiosolutions.com . Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent. Investor Contact:

Azur Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Azur Pharma Rank

Azur Pharma Frequently Asked Questions (FAQ)

  • When was Azur Pharma founded?

    Azur Pharma was founded in 2005.

  • Who are Azur Pharma's competitors?

    Competitors of Azur Pharma include Nora Pharma, Alpex Pharma, Tubilux Pharma, Auxilium Pharmaceuticals, Peckforton Pharmaceuticals and 12 more.

Compare Azur Pharma to Competitors

X
Xanodyne Pharmaceuticals

Xanodyne Pharmaceuticalsis a speciality pharmaceutical company focused on products for women's health care and pain management.

R
ROXRO Pharma

Roxro Pharma is an early-stage specialty pharmaceutical company dedicated to identifying, licensing, and developing compounds in specialized disease areas with significant sales potential, such as pain management. Roxro will pursue product development with the objective of commercializing these products. Niche products will not be developed by major pharmaceutical companies because they will not fuel their growth requirements. Foreign and biotechnology companies with compounds that have a limited sales potential will not be partnered with major pharmaceutical companies. Therefore there are a number of products not being developed even though they are efficacious, safe and satisfy an unmet medical need.

N
Naxospharma srl

greece vacation pharmaceutical company athens hotel naxos pharma travel tour

T
TheraQuest Biosciences

TheraQuest Biosciences, Inc. is building a diversified portfolio of pharmaceutical products to address pain management.

K
KeyBay Pharma

KeyBay Pharma is dedicated to the discovery, development and commercialization of antibiotics.

I
Ikano Therapeutics

Ikano Therapeutics is a specialty pharmaceutical company focused on developing nasally delivered pharmaceutical products with a particular focus on drugs treating pain and disorders related to the central nervous system.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.